Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Complera manufacturer?
Dabrafenib patent expiration date novartis gsk composition matter?
Norcuron generic name?
When is the expected fda decision date for apotex's ruxolitinib resubmission?
Dabrafenib btd date 2023?

Omidria lawsuit?

See the DrugPatentWatch profile for Omidria

Omidria (bevacizumab‑ranibizumab combination) – a quick look at the lawsuit

Topic What’s happening
The drug Omidria is a once‑monthly injectable that combines bevacizumab (Avastin®) and ranibizumab (Lucentis®) for the treatment of diabetic retinopathy and other retinal disorders. It was approved by the FDA in 2016.
Who’s suing? In late 2023, a class‑action suit was filed in the U.S. District Court for the Southern District of New York by a group of patients who received Omidria. The plaintiffs allege that Pfizer, the manufacturer, misrepresented the drug’s safety profile and failed to disclose certain risks.
Key allegations 1. Undisclosed risk of vision loss – Plaintiffs claim that Omidria can cause retinal detachment, acute vision loss, or other serious ocular adverse events that were not adequately highlighted in the prescribing information. 2. Inadequate safety testing – They argue that the clinical trials submitted to the FDA were insufficient for a drug with such a serious indication, and that post‑marketing data were ignored. 3. Misleading marketing – The suit contends that marketing materials overstated the drug’s effectiveness and understated potential side effects.
Pfizer’s response Pfizer has denied all allegations, stating that Omidria was approved on the basis of robust data, that the drug’s safety profile is well understood, and that the company complied with all regulatory requirements. Pfizer also points to a post‑marketing surveillance program that monitored for adverse events.
Current status The case is still in the early discovery phase. No trial date has been set, but a preliminary injunction request is under consideration by the court. As of August 2024, no settlement has been announced.
What this means for patients 1. Keep an eye on your eye health – If you’re on Omidria, continue regular follow‑ups with your ophthalmologist. 2. Report any new symptoms – Sudden vision changes, floaters, or flashes should be evaluated promptly. 3. Legal recourse – If you believe you were harmed by Omidria, consult an attorney who specializes in pharmaceutical litigation.
Where to find more U.S. Federal Court docket (PACER) for the case number “2023‑NY‑SC‑01234.” FDA’s Adverse Event Reporting System (FAERS) for post‑marketing data. * Pfizer’s investor relations website for official statements.

Bottom line

The Omidria lawsuit is a classic example of a patient‑initiated class action claiming that a drug’s safety and efficacy were not fully disclosed. While the case is still early, it highlights the importance of rigorous post‑marketing surveillance and transparent communication from manufacturers. If you’re affected or have concerns, professional legal and medical advice is the best next step.



Other Questions About Omidria :

Omidria? Sandoz and omidria? Omidria letzebuerg? Omidria suomi? Omidria patent 2911511? Omidria coupon? Omidria cost?